Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B
Michael Somenek, a clinical investigator in the groundbreaking Galderma study, notes that as medication-driven weight loss becomes more prolific around the world, so do the associated impacts of facial volume loss and other unwanted cosmetic effects like shadowing and hollowness. The Science Behind Facial Changes with GLP-1 Medications The 2025 Galderma clinical trial confirms what weve been observing in our practice at Aestha Clinic
Terushkins office if unsure
Heres what we know about its timeline: Current status: Phase 3 clinical trials underway Expected FDA submission: Late 2025 or early 2026 Potential approval: Late 2026 to early 2027, though delays are common Market availability: Likely 2027, assuming trials remain positive If youre interested in accessing retatrutide now, you may be able to join a clinical trial
It's also used to stimulate libido in men
Since statins are highly protein-bound, displacement by other drugs is unlikely to cause clinically significant interactions (Palleria et al